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ABSTRACT 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that are activated in 
response to various stimulants, and they regulate many processes including inflammation; 
the stress response; gene transcription; and cell proliferation, differentiation, and death. 
Increasing reports have shown that the PI3Ks and their downstream effector Akt are 
activated by several platelet receptors that regulate platelet activation and haemostasis. 
Platelets express two immunoreceptor tyrosine based activation motif (ITAM) receptors, 
collagen receptor glycoprotein VI (GPVI) and Fcγ receptor IIA (FcγRIIA), which are 
characterized by two YxxL sequences separated by 6–12 amino acids. Activation of an 
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ITAM receptor initiates a reaction cascade via its YxxL sequence in which signaling 
molecules such as spleen tyrosine kinase (Syk), linker for activation of T cells (LAT) and 
phospholipase C γ2 (PLCγ2) become activated, leading to platelet activation. Platelets also 
express another receptor, C-type lectin 2 (CLEC-2), which has a single YxxL sequence, so 
it is appropriately called a hemITAM receptor. ITAM receptors and the hemITAM receptor 
share many signaling features. Here we will summarize our current knowledge about how 
the PI3K/Akt pathway regulates (hem)ITAM receptor-mediated platelet activation and 
haemostasis and discuss the possible benefits of targeting PI3K/Akt as an antithrombotic 
therapy. 
Abbreviation 
PI3K, phosphoinositide 3-kinases; ITAM, immunoreceptor tyrosine based activation motif; 
GPVI, glycoprotein VI; FcγRIIA, Fcγ receptor IIA; Syk, spleen tyrosine kinase; LAT, 
linker for activation of T cells; PLCγ2, phospholipase C gamma 2; CLEC-2, C-type lectin; 
vWF, von Willebrand factor; TxA2, thromboxane A2; GPCR, G protein-coupled receptor; 
TCR, T cell receptor; Lck, leukocyte-specific kinase; Zap-70, zeta-chain-associated protein 
kinase 70; CRP, collagen-related peptides; HEV, high endothelial venule; Grb2, growth 
factor receptor-bound protein-2; Gads, growth factor receptor-bound protein-2 adaptor 
downstream of Shc; PTEN, phosphatase and tensin homologue deleted on chromosome 10; 
DAG, diacyl glycerol; SHIP, SH2 domain-containing inositol polyphosphatase; PKC, 
protein kinase C; CaMKK, Ca
2+
/calmodulin-dependent protein kinase kinase; SNP, single-
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nucleotide polymorphism; GSK3, glycogen synthase kinase 3; LiCl, lithium chloride; MEK, 
MAPK/ERK kinase; ERK, extracellular signal-regulated kinase 
Keywords 
Protein kinase B; Phosphatidylinositol 3-kinases; Platelets; C-type lectin; Glycoprotein VI 
1. Introduction 
Platelets are released from megakaryocytes in the bone marrow and have a short life, 
circulating in blood for about 9–10 days. Because they are fragments of megakaryocytes, 
they have no nucleus. Platelet activation is a vital step in both haemostasis: a physiological 
response that prevents significant blood loss following vascular injury and thrombosis: a 
pathological extension of normal haemostasis [1]. Platelets circulate in healthy vessels, but 
when a vessel wall is damaged, platelets become activated when they interact with the 
newly exposed subendothelial collagen. Platelets are tethered onto the site of injury through 
interaction of the glycoprotein (GP) Ib-V-IX complex with von Willebrand factor (vWF), 
which is bound to exposed collagen. This interaction enables collagen to interact with 
glycoprotein (GP) VI, thus initiating signaling events that lead to the conformational 
change (activation) of integrins αIIbβ3 and 21, enabling the former to bind to vWF and 
fibrinogen and the latter to bind to collagen. Following activation of these receptors, 
secondary mediators such as ADP and thromboxane A2 (TxA2) are secreted from platelets 
and activate ADP receptors and TxA2 receptors, further supporting the haemostatic and 
thrombotic function of platelets. Dysregulation or dysfunction of platelet signaling events 
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can lead to bleeding disorders or formation of arterial thrombosis; thus it is important to 
understand platelet signaling pathways so we can treat these disorders appropriately [1]. 
PI3K and its downstream effectors are activated by several platelet receptors, however 
inhibition of PI3K isoforms or their downstream effectors leads to only partial blockade of 
platelet activation and only has a significant effect in response to low agonist 
concentrations [1-3]. This characteristic therefore makes them very attractive targets for 
novel antithrombotic therapy reducing the risk of potential bleeding side effects, which 
current strategies have to negotiate. 
2. Platelet receptors 
Platelets are known to express a wide variety of receptors: G protein-coupled receptors 
(GPCRs) (thrombin receptors PAR-1 and PAR-4), integrins (αIIbβ3, α2β1, α5β1, α6β1, 
αvβ3), leucine-rich repeat (LRR) family receptors (GPIb/IX/V), ADP receptors (P2Y1 and 
P2Y12), TxA2 receptors (TPα and TPβ), immunoglobulin superfamily receptors (GPVI, 
FcγRIIA), and C-type lectin-like receptors (P-selectin and CLEC-2) [4] (Table1). Many of 
these receptors have had their signaling mechanisms investigated with data suggesting they 
share a high degree of similarity with the receptors activated under growth factors or 
hormones in nucleated cells. The common signaling pathways are activation of 
phospholipase C (PLC) and elevation of intracellular Ca
2+
, leading to secretion of 
secondary mediators to facilitate platelet activation and conversion of inactive integrin via a 
conformational change to its ligand-binding active state (inside-out signaling). Among 
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these signaling events, phosphoinositide signaling is active in platelets and has been shown 
to play a critical role in platelet activation [1]. 
3. Platelet ITAM receptors 
The immunoreceptor tyrosine based activation motif (ITAM) is a highly conserved 
sequence defined by Yxx(L/I)x6-12Yxx(L/I) which can be found in the cytosolic domain in a 
number of receptors and adaptor proteins. When phosphorylated, ITAMs serve as docking 
sites for SH2 domain containing tyrosine kinases which are critical for initiation of 
signaling cascades. GPVI is the major collagen receptor on platelets. Through association 
with the Fc receptor γ (FcRγ) chain, which contains two YxxL motifs, signal transduction is 
initiated  demonstrating that the GPVI-FcRγ complex is essential for GPVI signaling [5]. 
Other ITAM receptors of C-type lectin-like receptor (CLR) family such as dendritic cell-
associated C-type lectin-2 (Dectin-2) which is predominantly expressed in myeloid cells is 
also known to interact with FcRγ and signal through the YxxL sequences in FcRγ. 
GPVI/FcRγ is the only ITAM receptor expressed in mouse platelets, but human platelets 
express both GPVI/FcRγ and FcRIIA both of which signal through a tandem YxxL 
sequences. Platelet ITAM receptors utilize the same family of signaling proteins as ITAM 
receptors in other hematopoietic cells such as T cell receptor (TCR) and B cell receptor 
(BCR). GPVI uses predominantly Lyn and Syk and the PLCγ2 isoform, whereas the TCR 
uses leukocyte-specific kinase (Lck) and zeta-chain-associated protein kinase 70 (Zap-70) 
and the PLCγ1 isoform. Because of these similarities, it is possible to study the signaling 
pathways of the platelet ITAM receptors by transfecting platelet signaling proteins into T 
and B cell lines. 
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3.1. GPVI 
GPVI is a platelet-specific collagen receptor that is expressed on the platelet surface. 
Genetic deletion of GPVI in mice abolished the platelet response to collagen but the mice 
only exhibited a mild defect in haemostasis [6, 7]. Similarly, patients with a GPVI defect 
only show mild bleeding disorders [8, 9]. GPVI has two extracellular Ig domains, a mucin-
rich stalk and short cytoplasmic domain. The cytosolic tail of GPVI has a sequence for 
binding to calmodulin and one that binds to the SH3 domain of Src family kinases such as 
Fyn and Lyn. It is non-covalently associated with the FcRγ-chain homodimer, which 
contains an ITAM. Both GPVI and FcRγ are essential for collagen-induced platelet 
activation [5]. Once phosphorylated on two conserved tyrosines after GPVI engagement by 
collagen, the FcRγ chain is responsible for signal transduction. Phosphorylation of FcRγ 
chain leads to binding of the tyrosine kinase Syk, inducing downstream signaling cascades, 
which are similar to those of other immune receptors as described above[10]. FcRγ is also 
used by other ITAM receptors in the C-type lectin-like receptors such as Dectin-2 and 
MINCLE. In these cases, activation of Syk, PLCδ, CARD9-Bcl10-Malt-1 and MAPK 
pathways induce cytokine production in myeloid cells which is important for host defence 
[11]. However, these cell surface receptors including Dectin-2 are not expressed in platelets 
and thus the role of CARD9-Bcl10-Malt-1 pathway downstream of GPVI and C-type 
lectin-like receptor stimulation in platelets is unknown. 
Collagen is a powerful activator of platelets that activate both GPVI and integrin α2β1. A 
number of GPVI-specific ligands have been used to delineate the signaling pathways, 
including collagen-related peptide (CRP), which contains GPVI recognition motif GPO 
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(glycine-proline-hydroxyproline); GPVI-specific antibodies; and the snake venom toxin 
convulxin [12].  
 3.2. Fcγ Receptor IIA (FcγRIIA) 
FcγRIIA is the second ITAM receptor in human platelets. Unlike GPVI, FcγRIIA has its 
ITAM within its cytoplasmic tail. Since mouse platelets lack a gene equivalent to FcγRIIA, 
transgenic mice expressing human FcγRIIA have been generated. Mouse platelets 
expressing human FcγRIIA have enhanced spreading on fibrinogen and thrombus 
formation in vivo, and it has been proposed that this is due to enhanced integrin outside-in 
signaling [13]. FcγRIIA signals through the same pathways as GPVI; therefore, in this 
commentary we will focus on the signaling through GPVI as an ITAM receptor.  
4. Platelet hemITAM receptors 
The C-type lectin-like receptor CLEC-2 (encoded by the Clec1b gene), and the closely 
related receptor, Dectin-1 which is found on dendritic cells, are founder members of a novel 
class of signaling receptors defined by a single YxxL sequence and known as a hemITAM 
(ITAM-like) receptor. CLEC-2 is the only hemITAM receptor in platelets.  
4.1. CLEC-2 
CLEC-2 is a C-type lectin-like receptor that is highly expressed in platelets and to a lesser 
extent, in other cell types such as activated dendritic cells and B cells [14]. The first ligand 
to be identified for CLEC-2 was rhodocytin, which was purified from the Malayan pit viper, 
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Calloselama rhodostoma, by the groups of Huang [15] and Morita [16] in the 1990s. To 
date, the only endogenous ligand found for CLEC-2 is podoplanin. Podoplanin is a 
sialomucin-like glycoprotein expressed in a variety of cells but is absent from vascular 
endothelial cells and is ordinarily not expressed in the vasculature.  
In vitro studies have shown that treating platelets with CLEC-2 agonists activate platelets, 
inducing aggregation and secretion, identifying CLEC-2 as a platelet activating receptor 
[17]. We and others have previously shown using murine models that homozygous loss of 
CLEC-2 results in developmental defects in brain vasculature, lung inflation and 
lymphatics, and is associated with perinatal lethality [18, 19]. However, the role of CLEC-2 
in haemostasis and thrombus formation seems to be limited; CLEC-2-deficient mice show 
no or minimal elongation of tail bleeding times which is also seen in GPVI-deficient mice 
[19, 20]. These data indicate that mechanisms independent of CLEC-2 and GPVI mediate 
platelet activation or that platelet activation by other agonists such as thrombin and ADP 
are sufficient to form haemostatic clots in the tail.  
More recently, Herzog et al. showed that platelet CLEC-2 is important for maintaining high 
endothelial venule (HEV) barrier function during chronic inflammation [21]. Through 
interaction with podoplanin expressing-fibroblastic reticular cells, CLEC-2 dependent 
pathways were required to prevent vascular leak in HEV in reactive lymph nodes. 
Moreover, CLEC-2 has been reported to be involved in capturing HIV-1 virus particles and 
transferring of HIV-1 infection by platelets together with other receptors [22]. This is the 
only report implicating CLEC-2 in pathogen recognition.  It would be interesting to 
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speculate whether CLEC-2 plays a more general role in pathogen recognition since the 
structurally related receptor Dectin-1 is a known pattern recognition receptor (PRR). This 
family of proteins serve as protection against fungi recognising conserved microbial 
structures known as pathogen associated molecular patterns (PAMPs) leading to the 
activation of transcription factor nuclear factor-kappa B (NF-κB). Taken together these 
reports suggest CLEC-2 has a number of roles which are not related to haemostasis.  
5. Comparison of ITAM and hemITAM receptors  in platelets 
From the studies detecting signaling events and proteomic analysis it has been revealed that 
the CLEC-2 shares many of its signaling cascades with GPVI and signals through 
activation of Syk, Src and PLCγ2 using adaptor proteins such as LAT and SH2-containing 
leukocyte protein of 76kDa (SLP-76) [23]. Moreover, in vivo experiments on GPVI/CLEC-
2-double knockout mice indicated that loss of both receptors resulted in severe defects in 
haemostasis and arterial thrombus formation, whereas deletion of GPVI or CLEC-2 alone 
only resulted in a minor or negligible defect in haemostasis and thrombus stability. This 
suggests that there is considerable redundancy in the function of these two receptors in 
these events [24].  
Common signaling pathways in ITAM and hemITAM receptors in platelets are illustrated 
in Fig. 1. Upon ITAM and hemITAM receptor stimulation, the tyrosine residue in the YxxL 
motifs in both receptors becomes phosphorylated enabling Syk to bind through its two SH2 
domains and undergo both autophosphorylation and further phosphorylation by Src family 
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kinases [25]. These events occur after a delay of 10 seconds upwards after receptor 
stimulation.  
The next step in the signaling cascade is recruitment and phosphorylation of LAT by 
activated Syk. Phosphorylated LAT then serves as a platform that binds growth factor 
receptor-bound protein-2 (Grb2), growth factor receptor-bound protein-2 adaptor 
downstream of Shc (Gads) and PLCγ2. Adaptor protein SLP-76 is recruited to LAT by 
binding to Gads or Grb2 which are critical for full activation of PLCγ2. PI3K is also 
recruited to LAT and generates phosphatidylinositol (3,4,5)-triphosphate (PIP3) from 
phosphatidylinositol (4, 5)-bisphosphate (PIP2). Adaptor proteins Vav1 and 3 have also 
been shown to be recruited to the LAT signalosome by binding to SLP-76 and Syk to 
mediate PLCγ2 activation.   The binding of PLCγ2 to phosphorylated LAT and PIP3 on the 
plasma membrane further stabilizes its localization to LAT. In addition, PIP3 recruits the 
tyrosine kinases Btk and Tec which phosphorylate PLCγ2 leading to its activation. 
Activated PLCγ2 generates secondary messengers, inositol-1,4,5-triphosphate (IP3) and 
1,2-diacylglycerol (DAG), which release Ca
2+
 from the intracellular store and activate 
protein kinase C (PKC), respectively. These pathways lead to a common platelet activation 
cascade, resulting in platelet aggregation and dense granule secretion, which release the 
positive feedback mediator ADP and TxA2 formation. In addition, activation of PKC also 
leads to activation of Raf-1/MEK/ERK pathways; however, unlike Raf-1 pathway 
activation in Dectin-1, it is not clear if this leads to NF-κB activation.  
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Syk signaling can also activate NF-κB via CARD9/Bcl10/MALT1 downstream of other 
hemITAMs, such as Dectin-1, in myeloid cells. Although MALT1 and Bcl10 are expressed 
in platelets, it is currently unclear if following (hem)ITAM receptor activation this 
signaling pathway plays a direct role in platelet activation [26]. 
Although there are similarities between GPVI and CLEC-2 signaling, there are also 
quantitative and qualitative differences between these pathways (Fig. 2). First, GPVI uses 
the YxxL sequences in the associated FcRγ chain, whereas CLEC-2 uses YxxL sequence in 
its own cytoplasmic domain. Secondly, as described above, ITAM receptors use two YxxLs, 
whereas the hemITAM receptor CLEC-2 only has a single YxxL sequence motif. As a 
consequence, in ITAM receptors Syk binds to two YxxLs in a single receptor, whereas in 
hemITAM receptors, Syk binds to two phosphorylated receptors bridging them via its 
tandem SH2 domains [27]. Thirdly, there are differences in proximal signaling events; 
Suzuki-Inoue et al. have reported that platelets from mice deficient in SLP-76, which is an 
adaptor protein that binds to LAT, do not respond to GPVI agonists. This is consistent with 
the role of SLP-76 in other hematopoietic cells, including T cells where SLP-76 deficiency 
leads to a failure in T cell development [17, 28]. However, in CLEC-2 signaling, although 
platelets from SLP-76-deficient mice do not respond to a low concentration of CLEC-2 
agonist, this can be overcome by adding a high concentration [17]. Similar results were 
observed for platelets from Vav1/Vav3 double-deficient mice; they fail to respond to high 
concentration of GPVI-specific agonist, but although unresponsive to CLEC-2 agonist at 
low concentration, they respond normally to high concentration [17]. Taken together these 
results demonstrate that SLP-76 and Vav1/Vav3 are essential for GPVI signaling whereas 
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the requirement of these adaptor proteins are overcome at high agonist concentrations in 
CLEC-2 signaling. Moreover, these data may suggest that CLEC-2 may use other, as yet 
unknown, adaptor proteins for signaling. A fourth difference is in the role of secondary 
mediators used to reinforce platelet activation following GPVI or CLEC-2 activation. 
Pollitt et al. reported that blocking secondary mediators such as ADP and TxA2 can block 
platelet activation at a low concentration of GPVI agonists but this is overcome at higher 
concentrations. In contrast, under the same conditions, platelet activation through CLEC-2 
signaling is severely inhibited, including activation of Syk and downstream signaling 
events.  This was insurmountable using high concentrations of agonists in human platelets 
[29] but not in mouse platelets [30]. However, the exact mechanism of how these secondary 
mediators reinforce CLEC-2 signaling is unknown and ADP or TxA2 stimulation itself does 
not activate CLEC-2. Also, in this paper, they reported that blocking actin polymerization 
by cytochalasin D had no effect on maximum aggregation in GPVI-mediated platelet 
activation but CLEC-2-mediated platelet activation is inhibited. These data suggest that 
actin polymerization plays a key role in CLEC-2 signaling possibly by retaining CLEC-2 
signaling molecules near CLEC-2 [29]. Although it is reported in T cells that actin 
polymerization is important for immunological synapse formation, the role of actin 
polymerization on CLEC-2-mediated adhesion to other cells has not yet been identified. 
These observations demonstrate that although ITAM and hemITAM signaling in platelets 
share many signaling features, the regulation and importance of a number of signaling 
molecules downstream of Syk differ between these receptors.  
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To date there have not been any reports describing Syk-independent signaling events that 
occur during GPVI and CLEC-2-mediated platelet activation. This is in contrast to the 
hemITAM receptor Dectin-1 where Raf-1 can activate NF-κB independent of Syk in 
myeloid cells. Indeed, it has been reported that disruption of Syk activity completely blocks 
platelet aggregation and secretion in response to GPVI or CLEC-2 agonists [31]. However, 
it is noteworthy that Syk deficiency does not affect haemostasis whereas the GPVI/CLEC-2 
double knockout mouse has a severe defect in haemostasis suggesting that a Syk 
independent pathway may exist or that this is the consequence of loss of adhesion [24, 32]. 
6. PI3K and Akt 
The PI3K/Akt pathway is activated in response to various types of stimulation including 
growth factors, cytokines, integrin, hormones and extracellular matrix (ECM) proteins; and 
this pathway regulates a wide spectrum of cellular processes including cell cycle 
progression and cell survival. This is illustrated by the correlation of gain of function 
mutations in PI3K or Akt resulting in cancer development. Furthermore, inhibitory 
mutations on the phosphatase PTEN (phosphatase and tensin homologue deleted on 
chromosome 10), which is a negative regulator for PI3K/Akt, are also found in cancer.  
PI3Ks are family of lipid kinases that in platelets are reported to be activated and regulate 
platelet activation [33]. PI3Ks catalyze the conversion of plasma membrane lipid PIP2 to 
PIP3. There are three families of PI3K: class I, II and III. Class I PI3Ks phosphorylate PIP2 
to generate PIP3. They are heterodimeric proteins consisting of a catalytic subunit (p110α, 
p110β, p110δ and p110γ) and a regulatory subunit. According to their catalytic subunit, 
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class I PI3Ks are further divided into class IA that is composed of p110α, p110β and p110δ, 
each associating with a SH2-containing regulatory subunit (p50, p55 or p85) that binds to 
phosphorylated tyrosine residues in a Y(P)xxM motif. Class IB consists of one catalytic 
subunit p110γ associated with a regulatory subunit (p101 and p84), which is regulated by 
binding to G protein βγ subunits following GPCR activation. Human and mouse platelets 
express all class I PI3Ks but express p110δ at low level [34, 35]. Class II PI3Ks produce 
phosphatidylinositol (3) phosphate (PI3P) from phosphatidylinositol (PI) and also 
contribute to phosphatidylinositol (3,4) bisphosphate (PI(3,4)P2) production. Three 
monomers have been identified: ubiquitous PI3K-C2α and C2β and the liver specific PI3K-
C2γ. Finally, in class III, the only member is vascuolar protein sortin 34 (Vps34) that is a PI 
specific kinase that only generates PI3P and is ubiquitously expressed. The role of class I 
PI3Ks have been studied in platelets, however the role of class II and III PI3Ks are not 
known. Platelets also express PIP3 phosphatases that are known to regulate the level of 
PIP3 by converting PIP3 back to PIP2; PTEN, SH2 domain-containing inositol 
polyphosphatase 1 (SHIP1), and SHIP2 [33]. 
One of the major downstream effectors from PI3K is the serine/threonine kinase Akt (also 
known as protein kinase B). Mouse and human platelets express all three isoforms of Akt, 
namely Akt1, Akt2 and Akt3 [2, 36-39]. The activation of Akt is mainly mediated by PI3K, 
generating PIP3 that recruits Akt and the other PH domain-containing proteins to the 
plasma membrane, keeping Akt in proximity to its upstream kinases. The activity of Akt is 
regulated through phosphorylation of two residues, Thr308 and Ser473. Phosphorylation of 
Thr308 is mediated by phosphoinositide-dependent kinase 1 (PDK1), and phosphorylation 
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of Ser473 is mediated by mTORC2 [40-43]. Consistent with this, platelets from PDK1-
deficient mice have impaired platelet activation and Akt phosphorylation only at Thr308 
and have impaired thrombin-mediated platelet activation [42]. However, the importance of 
phosphorylation at Ser473 is unknown in platelets since an mTORC2 inhibitor had no 
effect on thrombin-mediated platelet activation [43]. In contrast, in other ITAM receptors 
such as TCR, T cells from mTORC2 deficient mouse has significant reduction in 
phosphorylation at Ser473 after stimulation and this leads to reduction in the Th2 cell 
response such as IL-4 production suggesting that Ser473 phosphorylation is indispensable 
for Akt activity [44]. 
7.1. PI3K in platelet activation 
Studies on the role of PI3K in platelets have used genetically modified mice lacking PI3K 
subsets and pharmacological approaches employing specific inhibitors for PI3Ks. Most of 
the studies investigating the role of PI3K in platelets have used two structurally distinct 
inhibitors, wortmannin and LY294002 that both inhibit class I and class II PI3Ks. From 
these studies, it has been reported that PI3Ks are expressed in platelets and play an 
important role in platelet activation in many processes by affecting Ca
2+
 mobilization, 
aggregation and platelet spreading in response to several agonists such as collagen, CRP or 
convulxin [45, 46], ristocetin/vWF [47], thrombin [36] and ADP [48]. However, the role of 
each PI3K isoform differs depending on the agonist.  
During GPVI signaling, it has been appreciated that PI3Ks are activated in two ways: 
directly by GPVI signaling and indirectly via the production of secondary mediators and 
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subsequent activation of the ADP and TxA2 receptors. In the presence of secondary 
mediator inhibitors to block indirect activation of PI3Ks, and the PI3K inhibitors 
wortmannin or LY294002, Akt phosphorylation, IP3 accumulation, Ca
2+
 elevation, P-
selectin expression and thrombus formation of human platelets were all suppressed 
demonstrating that direct activation of PI3K/Akt by GPVI signaling is important for 
platelet activation [46]. As discussed in Section 5, CLEC-2 signaling is highly dependent 
on secondary mediators. Therefore inhibition of platelet activation secondary mediators 
leads to an almost complete loss of CLEC-2 activation making it difficult to ascertain 
whether direct or indirect signaling is important for PI3K activation during CLEC-2 
signaling.  
The catalytic subunit for PI3Kα, p110α, is frequently mutated in various types of cancer,  
however its role in platelets is not well known. Using a PI3Kα specific inhibitor, PIK-75, it 
has been demonstrated that blocking PI3Kα partially inhibited Akt phosphorylation after 
GPVI stimulation [46, 49]. Moreover, it has been reported that both PI3Kα and PI3Kβ have 
a non-redundant function under GPVI stimulation,with both isoforms being required for 
full activation of PLCγ2, IP3 formation, Ca2+ elevation, thrombus formation and Rap1 
activation, supporting distinct roles for both isoforms during platelet activation [46].  
PI3Kβ is reported to be the major PI3K isoform regulating platelet activity downstream of 
several platelet receptors including GPCRs, such as P2Y12, and integrins through regulation 
of PLC activation and Ca
2+
 elevation. Consistent with these reports, collagen-induced 
aggregation, Ca
2+
 elevation, Rap1 activation and thrombus formation are impaired in mice 
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lacking the p85α regulatory subunit (inhibiting class IA PI3Ks) [35] or p110β catalytic 
subunit of PI3Kβ [50]. This impairment of platelet activation was not regulated by the 
function of PI3K as a scaffold protein since platelets from mice having the kinase dead 
mutation of PI3Kβ also had impaired platelet activation [51]. Studies using PI3Kβ specific 
inhibitors, TGX-221 and AZD6482, have also shown that it inhibits GPVI agonist-
mediated platelet activation including Ca
2+
 elevation [46].  
Studies to investigate the role of PI3Kγ in platelet function suggest activation of the kinase 
is specific to ADP-induced platelet activation, with platelets from mice lacking p110γ 
catalytic subunit of PI3Kγ demonstrating impaired aggregation to ADP, whereas the 
response to other agonists including collagen were normal [52]. 
PI3Kδ is highly enriched in leukocytes however expression in platelets is low compared to 
other PI3K isoforms. It has been reported that mouse platelets lacking the catalytic subunit 
of p110δ had slightly reduced aggregation to submaximal concentrations of CRP but had a 
normal response to GPCR agonists and spread normally on collagen [3]. This suggests that 
PI3Kδ plays a minor role in GPVI signaling, partially reducing aggregation only at low 
agonist concentrations.  This minor role in platelet activation is in contrast to its role in 
BCR and TCR signaling where the p110δ kinase dead mutant markedly impaired B cell and 
T cell maturation [53]. These studies on each PI3K isoform show that there is a distinct 
regulation of PI3K activation between different ITAM receptors in different hematopoietic 
cell types. The importance of each PI3K isoform in CLEC-2 signaling has not yet been 
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analyzed but it is important to investigate whether there is different dependency to that on 
GPVI. 
7.2. Akt in platelets 
As mentioned above, Akt is the main downstream effector for PI3K [7] and in most cases, 
including GPVI signaling, the activation of Akt is amplified by secretion of ADP in 
platelets [49, 54]. Additionally, PI3K-independent pathways of Akt regulation have been 
reported. Akt is phosphorylated by PKC and by Ca
2+
/calmodulin-dependent protein kinase 
kinase (CaMKK) in platelets; and in thrombin stimulation, early Akt phosphorylation was 
poorly sensitive to PI3K inhibitors [36, 55]. In contrast to these reports, under GPVI 
stimulation, treating platelets with wortmannin or LY294002 completely blocked the 
phosphorylation of Akt with or without ADP, demonstrating that Akt activation is initiated 
in a PI3K-dependent manner [49]. CLEC-2-mediated Akt activation is partially inhibited by 
a PKC inhibitor, whereas wortmannin and LY294002 completely blocked phosphorylation. 
This demonstrates that PI3K is the main upstream inducer for Akt activation in both GPVI 
and CLEC-2 signaling, but that in CLEC-2 signaling, PKC also partially supports 
activation of Akt by sustaining Akt phosphorylation at later timer point. It has also been 
reported that PKC inhibition reduces Akt phosphorylation in GPVI-mediated activation 
[49]. However, PKC inhibition also blocks ADP secretion therefore it is not clear if this is 
due to inhibition of direct phosphorylation of Akt by PKC or indirect inhibition by loss of 
ADP-dependent Akt phosphorylation.  
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Studying the function of Akt in platelets is predominantly achieved by using mice models 
with deletion of individual Akt isoforms. Among the genetically modified mice generated, 
only Akt1 deficient mice demonstrated a significant defect in response to collagen. 
Specifically, Akt1 deficiency reduced platelet aggregation and secretion after collagen 
stimulation, with prolonged tail bleeding times suggesting deletion of Akt1 is sufficient to 
impair haemostasis [2, 56]. In contrast, deletion of Akt2 resulted in a reduced platelet 
response to thrombin or TxA2 but a normal respond to collagen [2, 39, 57]. An enhanced 
defect was seen in mouse platelets lacking two Akt isoforms, accomplished by Akt2 
knockdown in Akt1-deficient mice since the double knock-out is lethal [9, 10]. These data 
indicate that Akt isoforms have both non-redundant and redundant roles in supporting 
platelet activation. Of importance to this review, during collagen-mediated platelet 
activation, Akt1 is the isoform preferentially activated and also contributes more directly to 
haemostasis.  
It has been reported that Akt3 deficient mice also respond normally to collagen stimulation, 
while having a reduced response to thrombin and TxA2 [39]. However, the role of Akt3 in 
platelet activation is controversial with Moore et al. reporting that although Akt3 is 
expressed in platelets, they were unable to detect activation of Akt3 after agonist 
stimulation [37].  
Pharmacological inhibitors for each isoform have not yet been developed however the role 
of Akt has also been studied using the pan Akt inhibitor MK2206. It has been shown to 
significantly suppress human platelet activation under both GPVI and CLEC-2 stimulation 
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in human platelets [37]. However, for GPVI, the Akt inhibitor did not completely block 
platelet aggregation even at a low agonist concentration. In contrast, during CLEC-2 
signaling, the Akt inhibitor almost completely blocked the aggregation and secretion at low 
concentrations of agonist. These differences of Akt dependency between GPVI and CLEC-
2 may be attributable to CLEC-2 being highly dependent on secondary mediator signaling 
compared to GPVI, as discussed earlier.  
For future investigations, it would be worthwhile to study the roles of the individual Akt 
isoforms in human platelets because it has been reported that a single-nucleotide 
polymorphism (SNP) in Akt2 is associated with reduced P-selectin expression after CRP 
stimulation in platelets [58]. However, the fact that Akt isoforms have a common domain 
organization and high sequence homology makes it a challenge to develop specific 
inhibitors for each isoform. Taken together these results using Akt isoform deficient mice 
or pharmacological inhibitors for Akt demonstrates a role of Akt in (hem)ITAM receptor 
mediated platelet activation. However, the precise mechanism by which Akt supports 
platelet activation remains poorly characterized and several candidates have been suggested 
as Akt substrates which is discussed in Section 8. 
8. PI3K and Akt effectors in platelet activation 
In ITAM and hemITAM signaling, several candidates are proposed as an effector under the 
PI3K/Akt pathway (Fig. 3). Akt is known to phosphorylate more than 100 substrates. 
Glycogen synthase kinase 3β (GSK3β) is known to be one of the main substrates for Akt in 
a wide range of cell types. GSK3β is reported to be a negative regulator for platelet 
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activation, inhibitors potentiating platelet aggregation and secretion, and being developed 
as a potential drug to treat diabetes, stroke, Alzheimer’s and other diseases. 
Phosphorylation of GSK3 at its N-terminal negative regulatory site (Ser21 and Ser9 in 
GSK3α and GSK3β, respectively) inhibits GSK3α/β activation [59]. Deficiency of Akt 
isoforms has been reported to partially inhibit GSK3β phosphorylation, suggesting that 
each isoform has a redundant role in regulating GSK3β. Several groups have reported that 
GSK3α/β inhibition potentiates platelet activation. The GSK3α/β inhibitors LiCl and 
SB216763 have been shown to potentiate thrombin-induced platelet activation but to inhibit 
collagen-stimulated platelet activation, suggesting an opposite role for GSK3α/β under 
GPCR and ITAM receptors [39, 60, 61]. Moreover, using a new specific inhibitor for 
GSK3α/β, CHIR-99021, Moore et al. have shown that thrombin-mediated platelet 
activation was potentiated in inhibitor-treated platelets. This was in contrast to CRP-
mediated platelet activation which was unaltered, further suggesting the differential 
regulation of platelet activation by GSK3α/β, resulting in a negative role in thrombin 
receptor signaling but positive or negligible role in GPVI signaling in platelets [37]. These 
discrepant results from the studies on GPVI signaling using GSK3α/β inhibitors which 
show a negative or no effect in GPVI-mediated platelet activation may be due to the 
different specificity of these inhibitors since LiCl and SB216763 inhibit GSK3α/β and 
several other kinases at the concentrations used in these studies [62]. Alternatively, 
collagen may regulate GSK3α/β downstream of integrin α2β1, which is not activated by 
CRP. In CLEC-2 signaling, the role of GSK3α/β appears to be inhibitory and GSK3α/β 
inhibitors potentiate platelet activation to rhodocytin.  
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Another potential effector under PI3K activation is ERK (extracellular signal-regulated 
kinase), one of the MAPKs (mitogen-activated protein kinases). A series of studies have 
reported that, dependent on the conditions, activation of MAPK plays a minor role in 
platelet activation by GPCRs and GPVI [63, 64]. Studies on the involvement of MAPK in 
platelet function have been performed using pharmacological inhibitors. The MEK 
(MAPK/ERK kinase) inhibitors U0126 and PD98059 that inhibit ERK activation have been 
shown to inhibit platelet aggregation and secretion [64, 65]. On the other hand, Börsch-
Haubold et al. demonstrated that the MEK inhibitor PD98059 had no effect on platelet 
aggregation induced by collagen [65]. This discrepancy could be explained by the 
experimental conditions as the latter study was performed in the presence of a 
cyclooxygenase inhibitor that blocks TxA2 to counter the inhibitory effect of PD98059 
against this class of enzyme. These results however do not rule out the possibility that ERK 
may contribute to platelet activation by GPVI through the regulation of TxA2 formation 
(which is why ERK inhibitors had no effect under TxA2 blockage). Wortmannin treatment 
was shown to inhibit the ERK phosphorylation in collagen-stimulated platelets at a later 
time point [66]. These observations suggest a role of PI3K in phosphorylating ERK at a 
later time point which could sustain ERK activation and support platelet activation 
following both GPVI and CLEC-2 stimulation. 
In addition to activating Akt and ERK, PIP3 generation by PI3K can lead to the recruitment 
of PLCγ2, Btk and Tec, inducing PLC activation which is a key player in platelet activation 
as described in Section 5 [67-69]. This inhibition of PLC activation by PI3K inhibition can 
lead to impaired Ca
2+
 elevation, integrin inside-out signaling and PKC activation, 
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influencing more diverse pathways than just Akt or ERK activation. Consistent with this, it 
has been reported that PI3K inhibitors inhibit PLCγ2 activation as shown by impaired Ca2+ 
elevation in LY294002 or wortmannin treated platelets after GPVI stimulation 
demonstrating PLCγ2 is regulated by PI3K [45, 46]. 
9. PI3K/Akt pathways in human diseases and drug development  
As mentioned above, Akt is the main downstream effector for PI3K and has been 
demonstrated to play a role in platelet activation in (hem)ITAM receptors and haemostasis. 
Consistent with these reports using mouse models, expression of a SNP in the Akt2 
associated with human platelet response in a screening of 500 healthy European individuals 
suggests a role of Akt in human thrombosis or bleeding disorders [58]. Moreover, in the 
PI3K family, a SNP associated with PI3Kγ expression was also found to associate with 
changes in mean platelet volume and annexin V binding [70]. These observations further 
suggest a role for the PI3K/Akt pathway in human bleeding disorders and cardiovascular 
diseases. However, the functional redundancy of each isoform of PI3K or Akt could make 
it rather unlikely that a defect in a single isoform would result in the development of a 
disease. 
In the regulation of ITAM and hemITAM receptors in platelets, patients lacking GPVI 
display only a mild bleeding tendency and mice with either a GPVI or CLEC-2 deficiency 
have only a mildly prolonged tail bleeding time and reduced thrombus stability. These 
minor effects of GPVI and CLEC-2 on general haemostasis make them a good therapeutic 
target for anti-thrombotics without bleeding side effects. To date, Akt seems to be a good 
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therapeutic target that is differentially involved in GPVI and CLEC-2 signaling, having a 
partial effect on GPVI signaling and blocking CLEC-2 signaling. Moreover, molecules 
involved in the PI3K/Akt pathway are known to be frequently mutated in cancer patients 
[71], and cancer patients are at a high risk of developing venous thromboembolism, making 
it essential to treat these patients with anti-thrombotic drugs. An Akt inhibitor may be ideal 
for treating cancer patients since it has a relatively mild effect on GPVI- and CLEC-2-
mediated platelet activation in haemostasis and also can block development of the cancer. 
In PI3K-regulating therapy, an inhibitor targeting PI3Kβ would seem to be ideal for this 
purpose based on the data obtained from PI3K-deficient mice and inhibitors. However, the 
PI3Kβ inhibitor TGX-221, which has been reported to reduce adhesion to fibrinogen and 
to reduce thrombosis in a rat injury model, had no effect on haemostasis as assessed by tail 
bleeding time in rats [72]. Moreover, as a treatment against cancers and tumors, the pan Akt 
inhibitor MK2206 is now in a phase 2 trial; further, combination of this inhibitor with other 
anticancer agents such as receptor tyrosine kinase inhibitors, has been found to augment the 
efficiency of this antitumor therapy [73]. 
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Figure Legends 
Figure 1. (hem)ITAM receptor signaling 
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Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces the 
recruitment and subsequent activation of Syk. Activated Syk induces activation of signaling 
cascades that lead to the activation of PLCγ2 and elevation of intracellular Ca2+ level for 
which the adaptor protein LAT serves as a platform for this signaling cascade. This leads to 
granule secretion, integrin activation and aggregation of platelets which reinforces platelet 
activation. 
 
Figure 2. Comparison of GPVI and CLEC-2 signaling 
(i) ITAM receptor GPVI interacts with the covalent dimer of FcR-γ chain, in which each 
monomer contains an ITAM sequence. Activation of GPVI receptor leads to a one-to-one 
interaction of FcR-γ chain with Syk to activate Syk. The hemITAM receptor CLEC-2 
requires two phosphorylated receptors to activate Syk. (ii) SLP-76 is essential for GPVI 
signaling, whereas in CLEC-2 signaling, a high dose of agonist can overcome SLP-76 
deficiency. (iii) Platelets from Vav1/Vav3 double knockout mice fail to respond to high 
dose of GPVI agonist, whereas they respond to high dose of CLEC-2 agonist. (iv) Blocking 
actin polymerization almost completely blocked CLEC-2-mediated platelet aggregation, 
but it does not change the maximum aggregation in GPVI-mediated platelet aggregation. 
(v) At high dose of agonist, secondary mediators are dispensable in GPVI signaling 
whereas they are indispensable in CLEC-2 signaling. 
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Figure 3. Effectors under the PI3K/Akt pathway 
Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces activation 
of PI3K which generates PIP3 in the plasma membrane. This induces the activation of Akt, 
which then phosphorylates GSK3. Inhibition of GSK3 by Akt suppresses platelet activation 
in GPVI signaling but potentiates activation in CLEC-2 signaling. PI3K also directly or 
indirectly activates MEK and ERK, supporting platelet activation. PIP3 generation by PI3K 
can also lead to activation of PLCγ2 by recruiting PLCγ2, Btk and Tec to the plasma 
membrane to induce calcium elevation, PKC and platelet activation. 
 
Table 1 Overview of the receptors expressed in platelets 
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Receptor Ligand Receptor type 
   
PAR1 (only 
in human) 
Thrombin, PAR1 peptide (synthetic) G protein-coupled receptor 
 
PAR4 
 
Thrombin, PAR4 peptide (synthetic) 
 
G protein-coupled receptor 
 
P2Y1 
 
ADP 
 
G protein-coupled receptor 
   
P2Y12 ADP G protein-coupled receptor 
 
TP 
 
TxA2, U46619 (synthetic) 
 
G protein-coupled receptor 
 
GPVI 
 
Collagen, Laminin, CRP (synthetic), 
Convulxin (snake toxin), JAQ1 
(antibody) 
 
Ig 
 
α2β1 
 
collagen 
 
Integrin 
 
α6β1 
 
Laminin 
 
Integrin 
 
GPIb-XI-V 
 
vWF, Ristocetin (snake toxin) 
 
Leucine-rich 
 
αIIbβ3 
 
Fibrinogen, vWF 
 
Integrin 
 
P2X1 
 
CLEC-2              
 
ATP 
 
Podoplanin, Rhodocytin (snake toxin) 
 
Ca2+ channel 
 
C type lectin-like 
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